TURKISH JOURNAL OF UROLOGY, cilt.44, sa.2, ss.132-137, 2018 (ESCI)
Objective: The incidence of prostate adenocarcinoma (PCa) is increased with the use of prostate-specific antigen (PSA). In the current study, we aimed to investigate the impact of 5-alpha-reductase inhibitors (5-ARI) on pathological progression in patients followed by active surveillance (AS).